Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 17/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GALK1 | P51570 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614999 | 1.00 | PDK2 (0.46) | PDK2LMNASMN1; SMN2MEN1APAF1 | |
| SCHEMBL13078946 | 0.95 | PDK2 (0.40) | PDK2LMNASMN1; SMN2THRBHTT | |
| SCHEMBL13614995 | 0.94 | PDK2 (0.43) | PDK2LMNASMN1; SMN2MEN1APAF1 | |
| SCHEMBL13614996 | 0.94 | PDK2 (0.43) | PDK2LMNASMN1; SMN2MEN1APAF1 | |
| SCHEMBL13078913 | 0.94 | PDK2 (0.41) | PDK2LMNASMN1; SMN2MAPTTHRB | |
| SCHEMBL12564875 | 0.94 | PDK2 (0.41) | PDK2LMNASMN1; SMN2MEN1HTT | |
| SCHEMBL13615003 | 0.94 | PDK2 (0.41) | PDK2 | |
| SCHEMBL13615004 | 0.90 | PDK2 (0.40) | PDK2LMNASMN1; SMN2MEN1MAPT | |
| SCHEMBL13820011 | 0.89 | PDK2 (0.47) | PDK2SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL13078932 | 0.89 | KDM4E (0.38) | PDK2LMNASMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612204-B2 | Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612204-B2 | Quinoxaline derivative, and light-emitting element and light-emitting device using quinoxaline derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20080091012-A1 | Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080091012-A1 | Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091012-A1 | Quinoxaline Derivative, And Light-Emitting Element And Light-Emitting Device Using Quinoxaline Derivative | NQO1, GLB1, PDXK | PDK2 363/4885LMNA 3244/4885SMN1; SMN2 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.